Search results
Results from the WOW.Com Content Network
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Monoclonal antibody therapy may prove to be beneficial for cancer, autoimmune diseases, and neurological disorders that result in the degeneration of body cells, such as Alzheimer's disease. Monoclonal antibody therapy can aid the immune system because the innate immune system responds to the environmental factors it encounters by ...
Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer. [17] It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3. [17]
Treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC3+) biliary tract cancer as detected by an FDA approved test [2] Zenocutuzumab: Treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior ...
Cancer is the major cause of deaths in the recent era. Cancer types and stages have enhanced with time and so has efforts to treat cancer. Currently, there are about 369 cancer vaccine studies ongoing all around the world. [11] There are three cancer therapeutic vaccines which are approved by USA Food and Drug Administration, as following;
The US Food and Drug Administration (FDA) approved it in March 2017, for the treatment of Merkel-cell carcinoma, [84] an aggressive type of skin cancer. The EMA approved it in September 2017, for the same indication. [86] This is the first FDA-approved treatment for metastatic Merkel-cell carcinoma, a rare, aggressive form of skin cancer. [84]
Muromonab-CD3 was approved by the U.S. Food and Drug Administration (FDA) in 1986, [5] making it the first monoclonal antibody to be approved anywhere as a drug for humans. In the European Communities , it is the first drug to be approved under the directive 87/22/EWG, a precursor of the European Medicines Agency (EMA) centralised approval ...
Nadofaragene firadenovec (Adstiladrin): treatment for bladder cancer [13] Obecabtagene autoleucel (Aucatzyl): treatment of acute lymphoblastic leukemia [14] [15] Onasemnogene abeparvovec (Zolgensma): AAV-based treatment for spinal muscular atrophy [16] Strimvelis: treatment for adenosine deaminase deficiency (ADA-SCID)